Our Impact
The Monash Institute of Pharmaceutical Sciences (MIPS) is a dynamic, innovative and ambitious research institute, comprising over 400 scientists engaged in research in drug discovery, design, delivery and use. Our roots can be traced back to 1881.
Our therapeutic strengths lie in neuroscience and mental health, cardiovascular and metabolic health and global health. We are committed to research translation and had made major contribtuions to collaborative drug discovery programs that have progressed more than 30 novel drug candidates into clinical development
-
Ranked #1 in the Asia Pacific
-
Top 2 in the World
-
Scientific expertise
-
30 novel drug candidates
-
2000 undergraduate students
-
350 publications per year
Influenza therapies
The drug Zanamavir was a first in class antiviral drug developed for the treatment and prevention of influenza and is marketed as Relenza. The medicinal chemistry program that underpinned the development of Relenza was conducted at MIPS
Saving Lives at Birth : Inhaled Oxytocin
The single biggest pregnancy-related cause of death is excessive bleeding during or after birth, a condition that is effectively managed in developed countries using the gold standard therapy, oxytocin. Professor Michelle McIntosh and her team at MIPS are developing oxytocin as an inhaled, acute use medicine for the treatment of post-partum haemorrhage.
Cancer Therapeutics
MIPS researchers lead the medicinal chemistry and drug candidate optimisation programs that drive the drug discovery programs within the Cooperative Research Centre for Cancer Therapeutics (now CANthera). These programs have led to major licencing deals that have delivered >$40m in commercial revenue with the potential to rise to $700m.
Malaria Drug Discovery
The Centre for Drug Candidate Optimisation (CDCO) has a successful research partnership with the Medicines for Malaria Venture (MMV), focused on the discovery and development of new drugs to treat malaria. The partnership has so far produced 7 drug candidates that have progressed into clinical development including one drug approved in India (Synriam).
